Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat.
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Although dihydrotestosterone (DHT) is the principal androgen in the prostate, testosterone can also act as an androgen in this tissue. To determine the relative potencies of testosterone and DHT in preventing prostate regression, castrated rats were implanted for 4 d with varying doses of testosterone in the presence or absence of the 5alpha-reductase inhibitor finasteride. In the absence of finasteride, testosterone in the prostate is converted to DHT, creating an intraprostatic DHT dose response. In the presence of finasteride, this conversion is blocked, and an intraprostatic testosterone dose response is achieved. DHT was 2.4 times more potent than testosterone at maintaining normal prostate weight and duct lumen mass, a measure of epithelial cell function. The two androgens were equipotent at preventing DNA fragementation and expression of testosterone-repressed prostate message, two measures of apoptosis (cell death). The intraprostatic testosterone concentration that results from finasteride treatment in rats is sufficient to inhibit apoptosis but will not maintain normal epithelial cell activity. In conclusion, whereas DHT is more potent than testosterone at stimulating prostate epithelial cell function as measured by ductal mass, the two androgens are equipotent at preventing prostate cell death after castration. These results explain why finasteride causes prostate involution in the rat with minimal evidence of prostate cell death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Steroid 5α-Reductase 2 Deficiency*
WILSON, J. D., GRIFFIN, J. E., & RUSSELL, D. W. (1993) · Endocrine Reviews · doi:10.1210/edrv-14-5-577 · Cited by 346
Cited by
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
Androgen receptor signaling in prostate cancer development and progression
Tindall, D., & Lonergan, P. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.83937 · Cited by 535
Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia
Bartsch, G., Rittmaster, R., & Klocker, H. (2002) · World Journal of Urology · doi:10.1007/s00345-002-0248-5 · Cited by 128
“To be maximally active in the prostate, testosterone must first be converted to dihydrotestosterone (DHT) by the enzyme 5a-reductase (Fig. 2). Studies in rats have demonstrated that, at equivalent androgen concentrations in the prostate, DHT is about twice as potent as testosterone [ 111 ].”
BackgroundSelf-citationDrury, J. E., Mindnich, R., & Penning, T. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.127779 · Cited by 51
van der Merwe, J., Brooks, N. E., & Myburgh, K. H. (2009) · Clinical Journal of Sport Medicine · doi:10.1097/jsm.0b013e3181b8b52f · Cited by 29
Androgen receptor abnormalities in castration-recurrent prostate cancer.
Nacusi, L. P., & Tindall, D. J. (2009) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.09.34 · Cited by 27
Metadata
- Authors
- Wright, A. S., Thomas, L. N., Douglas, R. C., Lazier, C. B., & Rittmaster, R. S.
- Venue
- Journal of Clinical Investigation
- Published
- 1996-12-01
- Volume
- 98
- Issue
- 11
- Pages
- 2558-2563
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2002205097
- Cited by
- 134
- References
- 1
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.